Mode
Text Size
Log in / Sign up
N/A Completed N=4,467

EZETROL® Re-examination Study (MK0653-175)(COMPLETED)

Source: ClinicalTrials.gov NCT01070953 ↗
Enrolled (actual)
4,467
Serious AEs
1.0%
Results posted
Nov 2011
Primary outcomePrimary: Participants With Any Clinical and/or Laboratory Adverse Experience While Being Treated With EZETROL® Within 14 Days After Treatment Discontinuation — 257 participants

Summary

This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of EZETROL® through collecting the safety information according to the Re-examination Regulation for New Drugs.

Outcome Measures

OutcomeResultp-value
PRIMARY
Participants With Any Clinical and/or Laboratory Adverse Experience While Being Treated With EZETROL® Within 14 Days After Treatment Discontinuation
257 —
PRIMARY
Mean Percent Change From Baseline to Treatment in Lipid Parameters
-21.23; 3.47; -24.06; -10.37 —
PRIMARY
Overall Efficacy Evaluation of EZETROL®
3029; 241; 39; 3309 —

Eligibility Criteria

Inclusion Criteria

  • Participants Who Receives EZETROL® In Usual Medical Practice
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01070953). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search